Apremilast (Otezla®) received FDA approval on March 21, 2014 for the treatment of adults with active psoriatic arthritis (PsA). It is the first oral medication in the U.S. with an approved indication for the treatment of PsA. The recommended dose is 30 mg BID
Depression and anxiety are more common among individuals with arthritis than among the general population. Yet, these mood disorders are still underdiagnosed and undertreated in arthritis patients despite data that depression and anxiety affect important outcomes such as functional ability, pain, and quality of life.
Many autoimmune diseases have a female predominance. Rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are no exception. Both of these diseases can affect young women in their reproductive years, but little is known about the impact of RA and SLE on a woman’s opinion regarding pregnancy or, further, how this translates into family planning.